The Business & Science Behind the GLP-1 Boom

Send us Fan Mail GLP-1 drugs have produced some of the most consistent weight loss results medicine has ever seen. The business of actually getting them to patients is a different story entirely. David E. Williams, President of Health Business Group, and John Driscoll, Chairman of UConn Health, break down the CVS Caremark formulary reversal on CareTalk, examining what it reveals about the economics of GLP-1 coverage, and why emerging clinical research on cancer, long COVID, and addiction may push these drugs far beyond their original indication. **🎙️⚕️ABOUT CARETALK** CareTalk is a weekly podcast that provides an incisive, no B.S. view of the US healthcare industry. Join co-hosts John Driscoll (President U.S. Healthcare and EVP, Walgreens Boots Alliance) and David Williams (President, Health Business Group) as they debate the latest in US healthcare news, business and policy. **✨THIS VIDEO BROUGHT YOU BY:** At PIM Health, we’re building real-time payment infrastructure where providers don’t wait weeks to get paid, patients don’t leave without knowing exactly what they owe, and employers stop flying blind on their own plan spend. AR burden, gone. Surprise bills, gone. Prior auth delays, gone. Denials and appeals, gone.  Learn what we’re building here **GET IN TOUCH** Follow CareTalk on LinkedIn Become a CareTalk sponsor Guest appearance requests Visit us on the web Support the show **⚙️CareTalk:  Healthcare. Unfiltered. is produced by** Grippi Media Digital Marketing Consulting.